Literature DB >> 7805767

5-HT1D receptor type is involved in stimulation of cell proliferation by serotonin in human small cell lung carcinoma.

M G Cattaneo1, E Palazzi, G Bondiolotti, L M Vicentini.   

Abstract

Serotonin (5-hydroxytryptamine, 5-HT), a neurotransmitter and vasoactive agent, is contained in two small cell lung carcinoma cell lines GLC8 and NCI-N-592 and is released in the culture medium. It also stimulates DNA synthesis in the same cell lines. In GLC8 cells this mitogenic effect is not counteracted by ketanserin, ICS 205-930 and GR 113-808 which are antagonists of the 5-HT2, 5-HT3 and 5-HT4 receptors, respectively. On the contrary, the antagonists metergoline, methysergide, SDZ 21-009 and methiothepin inhibit the 5-HT-stimulated incorporation of [3H]thymidine in GLC8 cells. The 5-HT1D agonist sumatriptan is capable of mimicking 5-HT action on cell proliferation. Both sumatriptan and 5-HT inhibit adenylate cyclase activity at doses which correlate with the mitogenic effect. We conclude that a 5-HT1D receptor type contributes to the mitogenic effect of 5-HT in GLC8 cells. This is the first demonstration of an involvement of the 5-HT1D receptor type in human cell proliferation. The design of specific antagonists for this type of receptor might be useful for the growth control of this very aggressive tumor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7805767     DOI: 10.1016/0922-4106(94)90068-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Synthesis of serotonin from 5-hydroxytryptophan in the post-crush retina: inhibition of in vitro outgrowth by the intraocular administration of the precursor.

Authors:  L Lima; M Urbina; P Matus; Y Drujan
Journal:  Neurochem Res       Date:  1996-08       Impact factor: 3.996

2.  Pharmacology of cloned human 5-HT1D receptor-mediated functional responses in stably transfected rat C6-glial cell lines: further evidence differentiating human 5-HT1D and 5-HT1B receptors.

Authors:  P J Pauwels; C Palmier; T Wurch; F C Colpaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

3.  Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions.

Authors:  P J Pauwels; A Gouble; T Wurch
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

4.  5-Hydroxytryptamine 5-HT1D receptors mediating inhibition of cyclic AMP accumulation in Madin-Darby canine kidney (MDCK) cells.

Authors:  P Schoeffter; I Bobirnac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-09       Impact factor: 3.000

5.  Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth.

Authors:  Gianfranco Alpini; Pietro Invernizzi; Eugenio Gaudio; Julie Venter; Shelley Kopriva; Francesca Bernuzzi; Paolo Onori; Antonio Franchitto; Monique Coufal; Gabriel Frampton; Domenico Alvaro; Sum P Lee; Marco Marzioni; Antonio Benedetti; Sharon DeMorrow
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

6.  Bioluminescence-based high-throughput screen identifies pharmacological agents that target neurotransmitter signaling in small cell lung carcinoma.

Authors:  Ma Reina D Improgo; Christopher W Johnson; Andrew R Tapper; Paul D Gardner
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

7.  5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viability.

Authors:  Yessenia Ballou; Alexandria Rivas; Andres Belmont; Luv Patel; Clarissa N Amaya; Shane Lipson; Thuraieh Khayou; Erin B Dickerson; Zeina Nahleh; Brad A Bryan
Journal:  Mol Clin Oncol       Date:  2018-07-19

8.  Anti-Tumor Potential of a 5-HT3 Receptor Antagonist as a Novel Autophagy Inducer in Lung Cancer: A Retrospective Clinical Study with In Vitro Confirmation.

Authors:  Jeong Soo Lee; Seong Yong Park; Na Young Kim; Dong Wook Kim; Ju Eun Oh; Eunjin Heo; Jong Seok Lee; Young Chul Yoo
Journal:  J Clin Med       Date:  2019-09-03       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.